NCT00395746View on ClinicalTrials.gov

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

May 31, 2008

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

sulfonylurea

SU agent

DRUG

liraglutide

Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.

DRUG

liraglutide

Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY